ABLIVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.16 SEK | -5.33% |
|
-2.08% | -34.83% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 215M 19.78M |
|---|---|---|---|---|---|
| Net income 2024 * | -142M -13.05M | Net income 2025 * | -157M -14.43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 124M 11.4M | Net cash position 2025 * | 173M 15.9M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.07
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.33% | ||
| 1 week | -2.08% | ||
| Current month | -1.36% | ||
| 1 month | +7.38% | ||
| 3 months | -33.19% | ||
| 6 months | -31.18% | ||
| Current year | -34.83% |
1 week
0.15
0.18
1 month
0.140.18
Current year
0.140.27
1 year
0.140.32
3 years
0.140.79
5 years
0.142.68
10 years
0.1482.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Director of Finance/CFO | 57 | 13-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.16 | -5.33% | 1,582,808 |
| 24-04-23 | 0.169 | +1.93% | 1,307,990 |
| 24-04-22 | 0.1658 | +3.88% | 2,787,638 |
| 24-04-19 | 0.1596 | -1.48% | 627,727 |
| 24-04-18 | 0.162 | -0.86% | 435,361 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT
More quotes
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
2024-05-20
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.83% | 20.99M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- ABLI Stock
